Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VIR BIOTECHNOLOGY, INC.

(VIR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Vir Biotechnology : GSK and Vir Biotechnology announce Joint Procurement Agreement with European Commission for COVID-19 treatment sotrovimab

07/29/2021 | 10:36am EDT

GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced they have signed a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of sotrovimab, an investigational single dose SARS-CoV-2 monoclonal antibody for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19.

The Joint Procurement Agreement enables participating European Union (EU) Member States to quickly purchase sotrovimab, following local emergency authorisation or authorisation at the EU level, to treat high-risk patients with COVID-19 who may benefit from early treatment with sotrovimab.

This action follows the positive scientific opinion issued by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), under Article 5(3) of Regulation 726/2004, which can be considered by the national authorities in EU Member States when taking evidence-based decisions on the early use of the medicine prior to marketing authorisation. Sotrovimab is included in the European Commission's portfolio of promising candidate therapies as part of its COVID-19 Therapeutics Strategy. In addition, the documentation to support the forthcoming marketing authorisation application for sotrovimab is under rolling regulatory review with the EMA. In June, the companies announced confirmatory full results for the Phase 3 COMET-ICE trial, which resulted in a 79% reduction (adjusted relative risk reduction) (p

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about VIR BIOTECHNOLOGY, INC.
09/17INSIDER SELL : Vir Biotechnology
MT
09/08VIR BIOTECHNOLOGY : to Participate in the Morgan Stanley 19th Annual Global Heal..
AQ
09/07Vir Biotechnology to Participate in the H.C. Wainwright 23rd AnnualáGlobal In..
GL
08/27U.S. resumes supply of Lilly's COVID-19 antibody combo to some states
RE
08/23VIR BIOTECHNOLOGY : Secures Provisional Marketing Approval for COVID-19 Treatmen..
MT
08/23VIR BIOTECHNOLOGY : Announces First Marketing Authorization for its First Commer..
AQ
08/23Vir Biotechnology, Inc. Announces First Marketing Authorization for Its First..
CI
08/20AstraZeneca's antibody therapy prevents COVID-19, study shows
RE
08/06SECTOR UPDATE : Health Care Pulls Back Ahead of Friday Opener
MT
08/06VIR BIOTECHNOLOGY : Swings to Surprise Profit in Q2 as Revenue Climbs
MT
More news
Analyst Recommendations on VIR BIOTECHNOLOGY, INC.
More recommendations
Financials (USD)
Sales 2021 399 M - -
Net income 2021 -206 M - -
Net cash 2021 1 004 M - -
P/E ratio 2021 -34,6x
Yield 2021 -
Capitalization 7 124 M 7 124 M -
EV / Sales 2021 15,4x
EV / Sales 2022 13,3x
Nbr of Employees 367
Free-Float 86,9%
Chart VIR BIOTECHNOLOGY, INC.
Duration : Period :
Vir Biotechnology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIR BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 54,54 $
Average target price 69,86 $
Spread / Average Target 28,1%
EPS Revisions
Managers and Directors
George A. Scangos President, Chief Executive Officer & Director
Howard Horn CFO, Secretary & Principal Accounting Officer
Vicki L. Sato Non-Executive Chairman
Michael E. Kamarck Chief Technology Officer
Phil Pang Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
VIR BIOTECHNOLOGY, INC.103.66%7 124
MODERNA, INC.311.65%173 588
LONZA GROUP AG32.35%60 074
IQVIA HOLDINGS INC.43.07%49 116
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-10.81%28 420